by MM360 Staff | Feb 24, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Marisa Wexler, MS | Feb 23, 2026 | Myeloma News
The U.S. Food and Drug Administration (FDA) has approved the combination of two oral therapies, Venclexta (venetoclax) and Calquence (acalabrutinib), for previously untreated adults with chronic lymphocytic leukemia (CLL), a form of blood cancer. The newly approved...
by MM360 Staff | Feb 21, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Feb 20, 2026 | Myeloma News
A cellular recycling process called autophagy helps determine whether pancreatic cancer cells grow quickly or hunker into survival mode to resist treatment, a study showed. The researchers found that autophagy in pancreatic cancer cells is regulated by connections...
by Marisa Wexler, MS | Feb 19, 2026 | Myeloma News
Telix Pharmaceuticals has submitted an application to European regulators seeking approval for TLX101-Px, the company’s experimental imaging agent designed to help guide treatment decisions in people with glioma. “We see a compelling opportunity in Europe to broaden...
